Vertex says about 20 patients have started sickle cell therapy, cuts two rare disease programs
Vertex Pharmaceuticals is picking up momentum in its strategy of branching out beyond cystic fibrosis.
About 20 patients have had their cells collected for Casgevy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
